XORTX Maps Q4 FDA IND Filing as XRx-026 Gout Program Moves Toward Its Next Regulatory Step

XORTX has put a date window around the next regulatory milestone

XORTX Therapeutics has outlined plans to submit an Investigational New Drug application to the U.S. Food and Drug Administration in the fourth quarter of 2026 for XRx-026, its gout program built around the proprietary XORLO formulation of oxypurinol.

The timing matters because it turns a broad development program into a defined regulatory sequence. An IND is the mechanism that allows a sponsor to seek authorization to conduct a clinical investigation in the United States. For XORTX, the planned filing is intended to support the next clinical work needed for a future marketing application.

Source: [1]

The development plan is built around a two-part clinical study

XORTX says the planned XRX-OXY-102 study is designed to generate pharmacokinetic and efficacy information needed for the FDA’s evaluation of a future New Drug Application. The company’s stated path includes agency meetings, completion of the two-part study and manufacture of commercial supply for the first year of a potential launch.

That creates a connected development chain. The formulation work, clinical program, regulatory interactions and manufacturing plan are being advanced as parts of the same strategy rather than as separate projects. XORTX says that, following successful completion of XRX-OXY-102, it anticipates seeking a pre-NDA meeting and preparing an NDA submission alongside pre-commercialization work.

XORLO gives XRx-026 a defined formulation strategy

XRx-026 is based on XORLO, XORTX’s proprietary formulation of oxypurinol. The company is developing the program as an alternative treatment option for people with gout who are not adequately served by existing xanthine oxidase inhibitor therapies.

From an investment-research perspective, the key point is that the program is not being presented as an early discovery-stage idea. XORTX is positioning it as a clinically advanced development effort with a named formulation, a planned U.S. regulatory filing and a defined study intended to bridge the program toward an NDA pathway.

Source: [2]

The company is connecting regulatory progress with manufacturing readiness

XORTX’s September 18 update also highlights commercial-supply manufacturing as part of the path toward a future marketing application. That is an important operational detail because later-stage drug development eventually requires more than clinical data; the sponsor also needs a reproducible product and manufacturing package that can support regulatory review and potential commercialization.

XORTX says it is targeting an NDA submission in approximately one year, subject to sufficient funding and timely completion of the XRX-OXY-102 study. The company also estimates the XRx-026 opportunity at more than US$700 million annually based on historical peak net sales for febuxostat. Those targets remain company estimates, but the September update makes the near-term roadmap clearer: IND submission, clinical execution, manufacturing and then the next FDA interaction.